GlassScriptPhysician profile
Elizabeth Bogovich
NPI 1578115432
$3,470.03
in general payments reported to CMS, 2019-2025
17 companies · $1,696 in 2025
The $1,696 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $401 · 2022: $602 · 2023: $605 · 2024: $166 · 2025: $1,696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,355 · Travel and Lodging: $1,112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,354.72 |
| Travel and Lodging | $1,111.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,691.10 | 2022-2025 | Minimed 780g |
| Dexcom, INC. | $269.03 | 2023-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $250.25 | 2022-2023 | |
| Astellas Pharma US INC | $173.19 | 2021 | |
| Antares Pharma, INC. | $147.55 | 2021-2023 | Nocdurna, Tlando, Xyosted |
| Teleflex LLC | $144.53 | 2022 | |
| Novo Nordisk INC | $124.99 | 2023 | Wegovy |
| Urovant Sciences INC | $124.80 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $119.93 | 2023 | Crysvita |
| Janssen Pharmaceuticals, INC | $118.71 | 2022 | |
| Janssen Biotech, INC. | $115.91 | 2021 | |
| Lilly USA, LLC | $75.82 | 2023-2024 | Jardiance, Zepbound |
| Insulet Corporation | $35.61 | 2024 | Omnipod |
| Olympus America INC. | $22.26 | 2023 | Uretero-Reno Fiberscope |
| Recordati_rare_diseases_inc. | $20.89 | 2023 | Signifor Lar, Isturisa |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sequel Med Tech, LLC | $18.02 | 2025 | Twiist |
| Chiesi USA, INC. | $17.44 | 2025 | Mycapssa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Bogovich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.